AMO viscoelastic gains FDA approval
Healon D latex-free viscoelastic (AMO) has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.
Healon D latex-free viscoelastic (AMO) has been granted premarket approval by the FDA. The clear dispersive ophthalmic viscosurgical device (OVD) is designed to be used during phacoemulsification, intraocular lens (IOL) implantation, keratoplasty and glaucoma filtration surgery.
Healon D has low viscosity and low molecular weight, allowing it to provide lubrication for IOL insertion and to remain coating the cornea throughout surgery, thereby providing endothelial cell protection. Healon D will be available in dual-packs with either standard Healon, or with Healon GV, an existing AMO OVD, which has a high viscosity and high molecular weight.
The packs containing Healon D will be available before the end of the year.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
